4.

# PHARMACIA/SEARLE **Global Patent Department** P.O. Box 1027 St. Louis, MO 63006

## **FACSIMILE TRANSMISSION** 703-746-5256

DATE: October 28, 2003

TO: U.S. Patent Office

Facsimile No. 703-746-5256

Attention: Examiner: Maryam Monshipouri, Ph. D.

**Group 1652** 

FROM: Scott J. Meyer

Reg. No. 25,275

Attorney for Applicant

RE: Application Ser. No. 10/043,452

Filed: January 10, 2002

Entitled: Protein Z-Dependent Protease Inhibitor

By: George J. Broze, Jr.

Assignee: Washington University

## SEE ATTACHED DOCUMENTS

- (1) TERMINAL DISCLAIMER
- (2) DEPOSIT ACCOUNT ORDER FORM (In duplicate) Account No. 1025

Number of Pages sent: 4 (including this cover sheet)

Transmitted from facsimile number 314-274-9095 Please contact our office if you encounter any problems in receiving this FAX transmission. Scott J. Meyer at 314-274-3117

PTO/SB/26 (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

## Docket Number (Optional) TERMINAL DISCLAIMER TO OBVIATE A DOUBLE PATENTING **REJECTION OVER A PRIOR PATENT** WU-3110/5 George J. Broze, Jr. In re Application of: -10/043,452 Application No.: January 10, 2002 Filed: Protein Z-Dependent Protease Inhibitor For: The owner Washington Univ. of 100 \_\_percent interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the Instant application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. 154 and 173, as presently so granted on the instant application shall be enforceable only for and during such period that it and the prior patent are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, Its successors or assigns. In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 and 173 of the prior patent, as presently shortened by any terminal disclaimer, in the event that it later; expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer. Check either box 1 or 2 below, if appropriate. For submissions on behalf of an organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the organization. I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of th United States Code and that such willful false statements may jeopardize the validity of the application or any patent Issu d thereon. 2. The undersigned is an attorney or agent of record. Scott J. Meyer Reg. No. 25,275 Typed or printed name (314) 274-3117 Telephone Number Terminal disclaimer fee under 37 CFR 1.20(d) included. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038. \*Statem intrunder 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner). Form PTO/SB/96 may be used for making this certification. See MPEP § 324.

This collection of information is required by 37 CFR 1.321. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Petent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

#### DEPOSIT ACCOUNT ORDER FORM

Via Facsimile No. 703-746-5256

To: Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Attention: Maryam Monshipouri, Ph. D. Group 1652

From: Scott J. Meyer - MC5S
Pharmacia Corporation
Global Patent department P.O. Box 1027
St. Louis, MO 63006

Please charge the Deposit Account No. 1025 with the \$110.00 fee for filing the attached Terminal disclaimer for:

Application Ser. No. 10/043,452

Filed: January 10, 2002 By: George J. Broze, Jr.

Entitled: Protein Z-Dependent Protease Inhibitor

The Commissioner is hereby authorized to charge any fees in addition to the above Deposit Account No. 1025 and to refund any overpayment as may be required.

Scott I Meyer

Reg. No. 25,275

Attorney for Applicant

#### DEPOSIT ACCOUNT ORDER FORM

Via Facsimile No. 703-746-5256

To: Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Attention: Maryam Monshipouri, Ph. D. Group 1652

From: Scott J. Meyer - MC5S
Pharmacia Corporation
Global Patent department P.O. Box 1027
St. Louis, MO 63006

Please charge the Deposit Account No. 1025 with the \$110.00 fee for filing the attached Terminal disclaimer for:

Application Ser. No. 10/043,452

Filed: January 10, 2002 By: George J. Broze, Jr.

Entitled: Protein Z-Dependent Protease Inhibitor

The Commissioner is hereby authorized to charge any fees in addition to the above Deposit Account No. 1025 and to refund any overpayment as may be required.

Scott J. Meyer

Reg. No. 25,275

Attorney for Applicant